• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Indivior PLC

    11/14/24 5:00:25 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $INDV alert in real time by email
    SC 13G/A 1 form_sc13ga-indivior.htm

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, DC 20549
    SCHEDULE 13G
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*
    Indivior PLC
    (Name of Issuer)
    Ordinary Shares, $0.50 nominal value per share
    (Title of Class of Securities)
    G4766E116
    (CUSIP Number)
    September 30, 2024
    (Date of Event Which Requires Filing of this Statement)
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    ☐ Rule 13d-1(b)
    ☐ Rule 13d-1(c)
    ☒ Rule 13d-1(d)

    (1)
    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be “filed’ for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


    CUSIP No. G4766E116
                 
    1.
     
    NAME OF REPORTING PERSONS:
     
    Scopia Capital Management LP
    2.
     
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
     
    (a) ☐ (b) ☐
    3.
     
    SEC USE ONLY
     
    4.
     
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON
    WITH
     
    5.
     
    SOLE VOTING POWER
     
    0
     
    6.
     
    SHARED VOTING POWER
     
    2,088,554
     
    7.
     
    SOLE DISPOSITIVE POWER
     
    0
     
    8.
     
    SHARED DISPOSITIVE POWER
     
    2,088,554
    9.
     
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    2,088,554
    10.
     
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
    11.
     
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    1.6%
    12.
     
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
    PN, IA



    CUSIP No. G4766E116
                 
    1.
     
    NAME OF REPORTING PERSONS:
     
    Scopia Management, Inc.
    2.
     
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
     
    (a) ☐ (b) ☐
    3.
     
    SEC USE ONLY
     
    4.
     
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    New York
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON
    WITH
     
    5.
     
    SOLE VOTING POWER
     
    0
     
    6.
     
    SHARED VOTING POWER
     
    2,088,554
     
    7.
     
    SOLE DISPOSITIVE POWER
     
    0
     
    8.
     
    SHARED DISPOSITIVE POWER
     
    2,088,554
    9.
     
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    2,088,554
    10.
     
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
    11.
     
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    1.6%
    12.
     
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
    CO, HC



    CUSIP No. G4766E116
                 
    1.
     
    NAME OF REPORTING PERSONS:
     
    Matthew Sirovich
    2.
     
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
     
    (a) ☐ (b) ☐
    3.
     
    SEC USE ONLY
     
    4.
     
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON
    WITH
     
    5.
     
    SOLE VOTING POWER
     
    3,423,067
     
    6.
     
    SHARED VOTING POWER
     
    2,088,554
     
    7.
     
    SOLE DISPOSITIVE POWER
     
    3,423,067
     
    8.
     
    SHARED DISPOSITIVE POWER
     
    2,088,554
    9.
     
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    5,511,621
    10.
     
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
    11.
     
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    4.3%
    12.
     
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
    IN, HC



    CUSIP No. G4766E116
                 
    1.
     
    NAME OF REPORTING PERSONS:
     
    Jeremy Mindich
    2.
     
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
     
    (a) ☐ (b) ☐
    3.
     
    SEC USE ONLY
     
    4.
     
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON
    WITH
     
    5.
     
    SOLE VOTING POWER
     
    0
     
    6.
     
    SHARED VOTING POWER
     
    2,088,554
     
    7.
     
    SOLE DISPOSITIVE POWER
     
    0
     
    8.
     
    SHARED DISPOSITIVE POWER
     
    2,088,554
    9.
     
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    2,088,554
    10.
     
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
    11.
     
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    1.6%
    12.
     
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
    IN, HC



    CUSIP No. G4766E116

             
    Item 1.
     
    (a).
     
    Name of Issuer:
         
           
    Indivior PLC (the “Issuer”)
         
       
    (b).
     
    Address of Issuer’s Principal Executive Offices:
         
           
    10710 Midlothian Turnpike, Suite 125
    North Chesterfield, VA  23235
         
    Item 2.
     
    (a).
     
    Name of Person Filing:
         
           
    Scopia Capital Management LP
    Scopia Management, Inc.
    Matthew Sirovich
    Jeremy Mindich
         
       
    (b).
     
    Address or Principal Business Office or, if None, Residence:
         
           
    Scopia Capital Management LP
    152 West 57th Street, 33rd Floor
    New York, NY 10019
     
    Scopia Management, Inc.
    Matthew Sirovich
    Jeremy Mindich
    c/o Scopia Capital Management LP
    152 West 57th Street, 33rd Floor
    New York, NY 10019
         
       
    (c).
     
    Citizenship:
         
           
    Scopia Capital Management LP is a Delaware limited partnership
    Scopia Management, Inc. is a New York corporation
    Matthew Sirovich is a United States citizen
    Jeremy Mindich is a United States citizen
         
       
    (d).
     
    Title of Class of Securities:
         
           
    Ordinary Shares, $0.50 nominal value per share (“Ordinary Shares”)
         
       
    (e).
     
    CUSIP Number:
         
           
    G4766E116
       
    Item 3.
     
    If this statement is filed pursuant to §§.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a:
         
       
    (a) ☐
     
    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
         
       
    (b) ☐
     
    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).


                         
       
    (c)
     
    ☐
     
    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
           
       
    (d)
     
    ☐
     
    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
       
    (e)
     
    ☒
     
    An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
           
       
    (f)
     
    ☐
     
    An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
           
       
    (g)
     
    ☒
     
    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
           
       
    (h)
     
    ☐
     
    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);
           
       
    (i)
     
    ☐
     
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
       
    (j)
     
    ☐
     
    A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
           
       
    (k)
     
    ☐
     
    Group, in accordance with §240.13d-1(b)(1)(ii)(K).
     
    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:
       
    Item 4.
     
    Ownership.
           
       
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
           
           
       
    Scopia Capital Management LP
           
         
       
    (a)
     
    Amount beneficially owned as of September 30, 2024:
         
           
    2,088,554
         
       
    (b)
     
    Percent of class as of September 30, 2024:
         
           
    1.6%
         
       
    (c)
     
    Number of shares as of September 30, 2024, as to which the person has:
             
           
    (i)
     
    Sole power to vote or to direct the vote
     
    0,
             
           
    (ii)
     
    Shared power to vote or to direct the vote
     
    2,088,554,
             
           
    (iii)
     
    Sole power to dispose or to direct the disposition of
     
    0,
             
           
    (iv)
     
    Shared power to dispose or to direct the disposition of
     
    2,088,554.


                     
    Scopia Management, Inc.
       
    (a)
     
    Amount beneficially owned as of September 30, 2024:
       
       
    2,088,554
       
    (b)
     
    Percent of class as of September 30, 2024:
       
       
    1.6%
       
    (c)
     
    Number of shares as of September 30, 2024, as to which the person has:
           
       
    (i)
     
    Sole power to vote or to direct the vote
     
    0,
           
       
    (ii)
     
    Shared power to vote or to direct the vote
     
    2,088,554,
           
       
    (iii)
     
    Sole power to dispose or to direct the disposition of
     
    0,
           
       
    (iv)
     
    Shared power to dispose or to direct the disposition of
     
    2,088,554.
       
    Matthew Sirovich
       
       
    (a)
     
    Amount beneficially owned as of September 30, 2024:
       
       
    5,511,621
       
    (b)
     
    Percent of class as of September 30, 2024:
       
       
    4.3%
       
    (c)
     
    Number of shares as of September 30, 2024, as to which the person has:
           
       
    (i)
     
    Sole power to vote or to direct the vote
     
    3,423,067,
           
       
    (ii)
     
    Shared power to vote or to direct the vote
     
    2,088,554,
           
       
    (iii)
     
    Sole power to dispose or to direct the disposition of
     
    3,423,067,
           
       
    (iv)
     
    Shared power to dispose or to direct the disposition of
     
    2,088,554.
       
    Jeremy Mindich
       
       
    (a)
     
    Amount beneficially owned as of September 30, 2024:
       
       
    2,088,554

                         
         
       
    (b)
     
    Percent of class as of September 30, 2024:
       
       
    1.6%
         
       
    (c)
     
    Number of shares as of September 30, 2024, as to which the person has:
             
           
    (i)
     
    Sole power to vote or to direct the vote
     
    0,
             
           
    (ii)
     
    Shared power to vote or to direct the vote
     
    2,088,554,
             
           
    (iii)
     
    Sole power to dispose or to direct the disposition of
     
    0,
             
           
    (iv)
     
    Shared power to dispose or to direct the disposition of
     
    2,088,554.
       
    Item 5.
     
    Ownership of Five Percent or Less of a Class.
       
       
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].
         
       
    Item 6.
     
    Ownership of More Than Five Percent on Behalf of Another Person.
       
       
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
       
       
    N/A
       
    Item 7.
     
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
       
       
    If a parent holding company or Control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary.
       
       
    N/A
       
    Item 8.
     
    Identification and Classification of Members of the Group.
       
       
    If a group has filed this schedule pursuant to ss.240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §§ 240.13d-1(c) or §§ 240.13d-1(d), attach an exhibit stating the identity of each member of the group.
       
      N/A



       
    Item 9.
     
    Notice of Dissolution of Group.
       
       
    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.
       
       
    N/A
       
    Item 10.
     
    Certification.
       
       
    N/A.


    SIGNATURES

    After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.
    Dated:  November 14, 2024
     
    SCOPIA CAPITAL MANAGEMENT LP
       
     
    By:
    Scopia Management, Inc.
    General Partner
         
     
    By:
    /s/ Matthew Sirovich
       
    Name:
    Matthew Sirovich
       
    Title:
    Managing Director


     
    SCOPIA MANAGEMENT, INC.
         
     
    By:
    /s/ Matthew Sirovich
       
    Name:
    Matthew Sirovich
       
    Title:
    Managing Director


      /s/ Matthew Sirovich
     
    MATTHEW SIROVICH


      /s/ Jeremy Mindich
     
    JEREMY MINDICH


    Get the next $INDV alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $INDV

    DatePrice TargetRatingAnalyst
    7/22/2025$20.00Buy
    Jefferies
    1/28/2025$16.00Buy
    Rodman & Renshaw
    7/23/2024$22.00Overweight
    Piper Sandler
    4/3/2024$37.00Buy
    Craig Hallum
    7/13/2023$35.00Outperform
    Northland Capital
    More analyst ratings

    $INDV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Jefferies resumed coverage on Indivior with a new price target

      Jefferies resumed coverage of Indivior with a rating of Buy and set a new price target of $20.00

      7/22/25 7:52:44 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rodman & Renshaw initiated coverage on Indivior with a new price target

      Rodman & Renshaw initiated coverage of Indivior with a rating of Buy and set a new price target of $16.00

      1/28/25 7:14:13 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Indivior with a new price target

      Piper Sandler initiated coverage of Indivior with a rating of Overweight and set a new price target of $22.00

      7/23/24 6:29:18 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INDV
    Financials

    Live finance-specific insights

    See more
    • Indivior to Report Second Quarter 2025 Financial Results and Host Webcast on July 31st

      RICHMOND, Va., July 17, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) today announced that it will report second quarter 2025 financial results on Thursday, July 31, 2025 at 7:00 a.m. U.S. ET.  Following the release of the financial results, Joe Ciaffoni, Chief Executive Officer, and other members of Indivior's leadership team will host a presentation via live webcast at 8:00 a.m. U.S. ET. Access to the Live Webcast Presentation: The webcast event and materials can be accessed on the "Investors" section of the company's website at www.indivior.com before the event beg

      7/17/25 9:00:00 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained

      SLOUGH, England and RICHMOND, Va., June 2, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its intention to cancel: (i) the secondary listing of the Company's Ordinary Shares ("Ordinary Shares") on the Equity Shares (Transition) category of the Official List (the "Official List") of the U.K. Financial Conduct Authority ("FCA"); and (ii) the admission to trading of its Ordinary Shares on the London Stock Exchange's ("LSE") main market for listed securities (together, the "London Delisting"). Background to and Reasons for the London Delisting In the circula

      6/2/25 2:00:00 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Indivior Announces Q1 2025 Financial Results

      SLOUGH, United Kingdom and RICHMOND, Va., April 24, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending March 31, 2025. The earnings release, investor presentation and webcast are available at www.indivior.com. The earnings release can be found at www.indivior.com/investorsThe investor presentation can be found at www.indivior.com/investors (at 7:00 am ET)There will be a live webcast presentation at 13:00 BST (8:00 am ET) hosted by Mark Crossley, CEO. The details are below. Webcast link: https://edge.media-server.com

      4/24/25 2:00:00 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INDV
    Leadership Updates

    Live Leadership Updates

    See more
    • Indivior Appoints Vanessa Procter as Executive Vice President of Corporate Affairs

      RICHMOND, Va., July 8, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) today announced the appointment of Vanessa Procter as Executive Vice President of Corporate Affairs, effective July 7, 2025. Vanessa is a seasoned corporate affairs leader with extensive experience in the biopharmaceutical industry, and will be responsible for Corporate Communications, Government Affairs, Policy and Advocacy at Indivior. "We are excited to welcome Vanessa to the Indivior team," said Joe Ciaffoni, Chief Executive Officer. "Vanessa has an impressive track record of aligning teams to pr

      7/8/25 8:00:00 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Indivior Appoints Tony Kingsley to the Board of Directors

      RICHMOND, Va., June 24, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) today announced the appointment of Tony Kingsley to the Board of Directors as an Independent Non-Executive Director, effective July 1, 2025. Mr. Kingsley was appointed pursuant to Indivior's relationship agreement with affiliates of Oaktree Capital Management, L.P., who supported his appointment. Tony Kingsley is an accomplished biopharmaceutical executive with a distinguished track record of building and leading organizations across multiple scientific disciplines, therapeutic areas, and stages of

      6/24/25 4:12:00 PM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Indivior Announces Patrick Barry as Chief Commercial Officer

      Seasoned commercial executive with more than 30 years of pharmaceutical experience RICHMOND, Va., May 27, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced the appointment of Patrick Barry as Chief Commercial Officer, effective June 2. In this role, Barry will lead the company's commercial growth strategy, execution, and operations as Indivior continues its mission to transform the treatment of opioid use disorder led by SUBLOCADE® (buprenorphine extended-release) Injection. Barry will join Indivior's executive committee. "Patrick is an accomplished and resp

      5/27/25 8:30:00 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INDV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Indivior Announces Completion of Cancellation of Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained

      SLOUGH, United Kingdom and RICHMOND, Va., July 25, 2025 /PRNewswire/ -- Further to the announcement made on June 2, 2025, Indivior PLC (NASDAQ:INDV) today announces that: (i) the secondary listing of the Company's Ordinary Shares ("Ordinary Shares") on the Equity Shares (Transition) category of the Official List of the UK Financial Conduct Authority; and (ii) the admission to trading of its Ordinary Shares on the London Stock Exchange's  main market for listed securities, have now been cancelled with effect from 08:00 a.m. UK time today, July 25, 2025 (the "London Delisting"). Indivior continues to maintain its primary listing of Ordinary Shares on the Nasdaq Stock Market.

      7/25/25 2:00:00 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Indivior Real World Evidence Study Finds Medications for Opioid Use Disorder, Particularly Extended-Release Buprenorphine, Reduced Odds of Emergency Department Visits for Patients with Opioid Use Disorder

      Extended-release buprenorphine (BUP-XR) had lower rates of hospitalizations, emergency department (ED) visits, and outpatient physician office visits compared to those receiving daily oral buprenorphine or no medications for opioid use disorder (MOUD)The study indicates BUP-XR may be an important tool in reducing ED visits, improving healthcare resource utilization and patient outcomesRICHMOND, Va., July 23, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced results from a new retrospective real-world study published in Drug and Alcohol Dependence Reports, which examined demographic and clinical factors associated with ED visits among adults diagnosed with opioid use disorder

      7/23/25 8:00:00 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Indivior to Report Second Quarter 2025 Financial Results and Host Webcast on July 31st

      RICHMOND, Va., July 17, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) today announced that it will report second quarter 2025 financial results on Thursday, July 31, 2025 at 7:00 a.m. U.S. ET.  Following the release of the financial results, Joe Ciaffoni, Chief Executive Officer, and other members of Indivior's leadership team will host a presentation via live webcast at 8:00 a.m. U.S. ET. Access to the Live Webcast Presentation: The webcast event and materials can be accessed on the "Investors" section of the company's website at www.indivior.com before the event beg

      7/17/25 9:00:00 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INDV
    SEC Filings

    See more
    • Indivior PLC filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - INDIVIOR PLC (0001625297) (Filer)

      6/30/25 7:03:38 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Indivior PLC filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

      8-K - INDIVIOR PLC (0001625297) (Filer)

      6/24/25 4:52:40 PM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Indivior PLC

      8-K - INDIVIOR PLC (0001625297) (Filer)

      6/2/25 6:06:09 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INDV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Indivior PLC

      SC 13G - INDIVIOR PLC (0001625297) (Subject)

      11/15/24 6:03:54 PM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Indivior PLC

      SC 13G/A - INDIVIOR PLC (0001625297) (Subject)

      11/14/24 5:00:25 PM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Indivior PLC

      SC 13D/A - INDIVIOR PLC (0001625297) (Subject)

      11/7/24 8:23:16 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care